Illumina is practically an institution in the biotech sector, but can it outgrow an aggressive competitor?
News & Analysis: Illumina
Which stock wins in a matchup between these two healthcare stocks?
COVIDSeq is the first COVID-19 diagnostic test based on gene sequencing to receive a green light from the regulator.
These three biotechs are hotly traded for good reason.
Illumina’s revenue woes may not be over as the coronavirus disruption continues, but the future still looks bright for this genome sequencing leader.
ILMN earnings call for the period ending March 29, 2020.
One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.
The biotech expects a tough second quarter, but maintains that its long-term prospects are solid.
Illumina shines as investors flock to shares less vulnerable to coronavirus disruptions.
This gene-sequencing pioneer hasn't been immune to the coronavirus' effects. But do Illumina's long-term prospects outweigh any short-term pain?